Sort by

Send to

Choose Destination

Search results

Items: 5


A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM.

Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. doi: 10.1002/acn3.214. Epub 2015 May 28.


Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.

Narayanan KL, Chopra V, Rosas HD, Malarick K, Hersch S.

Mol Neurobiol. 2016 May;53(4):2132-40. doi: 10.1007/s12035-015-9147-9. Epub 2015 May 5.


PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM.

Neurology. 2014 Mar 11;82(10):850-7. doi: 10.1212/WNL.0000000000000187. Epub 2014 Feb 7.


A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.

Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM.

Mov Disord. 2011 Aug 1;26(9):1691-7. doi: 10.1002/mds.23762. Epub 2011 May 24.


Changes in dried blood spot Hb A1c with varied postcollection conditions.

Buxton OM, Malarick K, Wang W, Seeman T.

Clin Chem. 2009 May;55(5):1034-6. doi: 10.1373/clinchem.2008.111641. Epub 2009 Mar 19. No abstract available.

Supplemental Content

Loading ...
Support Center